CD44 and cancer: In line with the results of TCGA dataset analysis (Fig EV3D), p‐TFCP2L1 expression (Fig 3D) was more associated with cancer‐specific survival than SALL4 or CD44 expression in the BC patient cohort (Fig 4E).